Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ReShape Lifesciences Inc

< Previous 1 2 Next >
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.